Aduro BioTech

Type: Company

Name: Aduro BioTech

First reported May 08 2013 - Updated May 08 2013 - 4 reports

Aduro Biotech Scientific Advisory Board Member Daniel A. Portnoy Elected to the National Academy of Sciences

Staying up-to-date has never been simpler. Sign up for the today! Aduro BioTech, Inc. announces that UC Berkeley Professor Daniel A. Portnoy has been elected to the (NAS), one of the highest honors given to a scientist in the United States. He is a member ... [Published BioSpace - May 08 2013]

Entities: Aduro BioTech, Advisory Board, University of California Berkeley, NAS

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Kohl's

The GEO Group Establishes at the Market Equity Offering Program

BOCA RATON, Fla. - (BUSINESS WIRE) - The GEO Group, Inc. (NYSE:GEO) ("GEO" ), the world's leading provider of diversified correctional, detention, and community reentry services, announced today that it has established an "at-the-market" equity offering ... [Published NewsBlaze - May 08 2013]

Entities: GEO Group Inc, Market, Kohl's

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Aduro BioTech announces collaboration with Johns Hopkins Cancer Center

3 minutes ago, 2:32am (ET) 05/01/2013 DatamonitorAduro BioTech, Inc., a biopharmaceutical company, has announced collaboration with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 in combination ... [Published Zecco - May 01 2013]

Entities: Aduro BioTech, Cancer, Skin Cancer, collaboration, Vaccine

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Johns Hopkins University

Aduro Teams with Johns Hopkins University to Evaluate Aduro Therapeutic Melanoma Vaccines in Combination with Anti-PD-1

Aduro BioTech, Inc. announced a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 ... [Published Individual.com - Apr 25 2013]

Entities: Skin Cancer, Johns Hopkins University, Aduro BioTech, Vaccine, Immunotherapy

First reported Apr 22 2013 - Updated Apr 23 2013 - 3 reports

New collaboration to expand vaccine approaches for melanoma

Aduro BioTech, Inc. announces a collaboration with Charles G. Drake, M.D., Ph.D., Associate Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center to evaluate the therapeutic approach of anti-PD-1 ... [Published News-Medical.Net - Apr 23 2013]

Entities: Skin Cancer, Vaccine, Aduro BioTech, collaboration

First reported Jan 31 2013 - Updated Jan 31 2013 - 1 reports

Aduro BioTech Closes on $6.5M

Aduro BioTech Inc. has completed an equity financing of $6.5 million. Details of the round, which came from “current investors” were not disclosed. The company is focused on vaccine platforms for the development of vaccines for cancer, infectious diseases ... [Published PE Hub News - Jan 31 2013]

Entities: Aduro BioTech, Vaccine, Stephen Isaacs, GVAX Pancreas

First reported Nov 30 2012 - Updated Nov 30 2012 - 1 reports

Phase II

Aduro completes enrollment in CRS207 and GVAX pancreas cancer vaccine Phase 2 trial

Aduro BioTech, Inc. announces completion of enrollment in the Phase 2 clinical trial of the sequential administration of two cancer vaccines, Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine, in patients with metastatic pancreatic cancer. Original Ar ... [Published BioPortfolio - Nov 30 2012]

Entities: cancer vaccine, Phase II, GVAX Pancreas, Aduro BioTech

Quotes

Dell OEM Solutions to manage integration and configuration of Dell Latitude laptops for FlySmart with Airbus " Class-2 Electronic Flight Bag solution Dell OEM Solutions will source, configure, and support the solution for Airbus' single-aisle ..."

The GEO Group Establishes at the Market Equity Offering Program [Published NewsBlaze - May 08 2013]

...Ph D , chief scientific officer at Aduro. "We are already on the cutting edge of combination immunotherapy for cancer and adding anti-PD-1 provides the potential for additional synergy and efficacy."

Aduro BioTech announces collaboration with Johns Hopkins Cancer Center [Published Zecco - May 01 2013]

"Let's go through this and see if there's a fit" Fox added, spending the next 10 minutes on the company's presentation and citing another huge potential market that is up the pharma's alley: oncology...

bwt04292013 [Published Pharmacy Choice - Apr 29 2013]

More Content

sort by: Date \| Relevance
Anna Protopapas replaces Deborah Dunsire as Mil... [Published FierceBiotech - May 10 2013]
Aduro Biotech Scientific Advisory Board Member ... [Published BioSpace - May 08 2013]
Aduro Biotech Scientific Advisory Board Member ... [Published BioSpace - May 08 2013]
Aduro Scientific Advisory Board Member Daniel A... [Published NewsBlaze - May 08 2013]
Aduro Scientific Advisory Board Member Daniel A... [Published Rock Hill Herald - May 08 2013]
The GEO Group Establishes at the Market Equity ... [Published NewsBlaze - May 08 2013]
Aduro Scientific Advisory Board Member Daniel A... [Published Business Wire Science: Science News - May 08 2013]
Aduro Scientific Advisory Board Member Daniel A... [Published Business Wire Health News - May 08 2013]
Aduro Announces Collaboration with Johns Hopkin... [Published NewsRX - May 03 2013]
Aduro BioTech announces collaboration with John... [Published Zecco - May 01 2013]
bwt04292013 [Published Pharmacy Choice - Apr 29 2013]
Aduro Teams with Johns Hopkins University to Ev... [Published Individual.com - Apr 25 2013]
Metastatic Hormone Refractory (Castration Resis... [Published Individual.com - Apr 23 2013]
New collaboration to expand vaccine approaches ... [Published News-Medical.Net - Apr 23 2013]
Aduro Biotech Announces Collaboration With John... [Published BioSpace - Apr 22 2013]
Aduro Announces Collaboration with Johns Hopkin... [Published BioPortfolio - Apr 22 2013]
Aduro Announces Collaboration with Johns Hopkin... [Published Business Wire Education News - Apr 22 2013]
Aduro Announces Collaboration with Johns Hopkin... [Published Business Wire Health News - Apr 22 2013]
Malignant Pleural Mesothelioma - Pipeline Revie... [Published Individual.com - Apr 19 2013]
Malignant Pleural Mesothelioma - Pipeline Revie... [Published PredictWallStreet - Apr 19 2013]
Melanoma Research Alliance awards $9.6 million ... [Published EurekAlert! - Apr 15 2013]
Aduro Announces Upcoming Presentations on Oncol... [Published EON Science - Apr 05 2013]
Aduro Announces Upcoming Presentations on Oncol... [Published Business Wire Science: Science News - Apr 05 2013]
Aduro Announces Upcoming Presentations on Oncol... [Published Business Wire Health News - Apr 05 2013]
Financings of the Fortnight Sees Signs That Poi... [Published The IN VIVO Blog - Feb 08 2013]
Aduro Announces Acquisition of GVAX Assets From... [Published EON Health & Medicine - Feb 04 2013]
Aduro Announces Acquisition of GVAX Assets From... [Published Business Wire Health News - Feb 04 2013]
Aduro BioTech Closes on $6.5M [Published PE Hub News - Jan 31 2013]
Aduro Announces $6.5 Million Financing [Published EON Health & Medicine - Jan 31 2013]
Aduro Announces $6.5 Million Financing [Published Business Wire Professional Services News - Jan 31 2013]